• Home
• cancer patients
• Black patients more likely to be excluded from pancreatic cancer clinical trials

Black patients more likely to be excluded from pancreatic cancer clinical trials

4.9 (168) · $ 18.99 · In stock

Medicina, Free Full-Text

Issue 13 - The Cancer Letter

Does gemcitabine-based combination therapy improve the prognosis

Disease-free survival as a surrogate endpoint for overall survival

Preclinical Studies for Safer Clinical Trials: Toxicokinetics

Impact of chemoradiotherapy on the survival of unresectable

SOM Discoveries 2022 VCU School of Medicine

Bassel El-Rayes named deputy director of O'Neal Comprehensive Cancer Center - The Cancer Letter

Neoadjuvant chemotherapy with or without radiotherapy versus